Before dog or cat studies,
clarify what should be tested in mice.
In companion animal drug, medical technology, and functional product development, evaluation in the species where the product will ultimately be used is essential. Precisely because dog and cat studies matter, teams should clarify mechanism, endpoints, biomarkers, candidate selection, and Go / No-Go criteria before entering them.
It is the study that fails without telling you why.
This page uses “dog or cat studies” and “species where the product will ultimately be used” as practical external-facing language for the regulatory concept of target-animal studies.
The social problem: the later a program fails, the larger the loss
Human drug development and Animal Health development differ in scale. Still, the same structural problem remains: when a program fails late without a clear explanation, time, budget, animal resources, and strategic opportunity are all lost.
Human drug development reference
Human drug development reference
>$2B
Note: Human drug development figures are not directly applied to Animal Health. They are shown as public reference points illustrating why late PoC and efficacy failure can strongly affect the overall development pathway.
Studies in the species where the product will ultimately be used are essential. But if mechanism, endpoints, dose, timing, target disease stage, and biomarkers are still unclear when those studies begin, negative or ambiguous results become difficult to interpret.
Regulatory and development context: nonclinical evaluation is not a “cheap preliminary step”
Public regulatory guidance and development materials emphasize objective evidence, appropriate study design, and scientifically justified evaluation. Nonclinical evaluation is part of building that rationale before higher-burden studies are conducted.
Effectiveness and safety are judged by data
Public Japanese materials on veterinary product approval describe nonclinical and clinical studies within the veterinary product lifecycle and emphasize objective data for judging effectiveness and safety.
Laboratory results may not always reproduce in clinical settings
Clinical and field settings can involve variable husbandry, concomitant medications, disease stage, and comorbidities. That is why the question to be tested should be defined before moving into dog or cat studies.
Study design itself determines development value
FDA CVM GFI #215 highlights the importance of agreement on effectiveness and target-animal safety protocols, including study design and statistical analysis planning before study execution.
MoA design
endpoint check
study design
dogs or cats
commercialization
Why mouse nonclinical evaluation?
The answer is not simply “because it is less expensive.” Mouse studies are not useful just because they are mouse studies. They are useful when the model and analyses are selected to match the development hypothesis, disease biology, endpoints, and readouts needed before dog or cat studies.
Explain why it should work
Evaluate whether the candidate affects the relevant disease biology, including inflammation, fibrosis, renal injury, immune response, tumor microenvironment, or other tissue-level mechanisms.
Decide what should be measured
Before entering dog or cat studies, clarify responsive endpoints, tissue assessments, biomarkers, imaging, gene expression, or other readouts that can explain response or non-response.
Prioritize what moves forward
Compare candidates, doses, timing, and combinations early, and identify which programs deserve dog or cat studies and which should be stopped or redesigned.
Mouse studies do not replace dog or cat studies.
They make them interpretable.
Mouse nonclinical evaluation is a scientific design stage before dog or cat evaluation. It helps make later results easier to understand and act upon.
What should be confirmed in mice is not only “whether it works”
Blood data, urine testing, clinical signs, and scores do not always explain where a candidate acts, why response occurs, or why response does not occur. This is where disease models and tissue-level analysis become important.
Tissue-level efficacy
Assess inflammation, fibrosis, tissue damage, lesion area, and other morphology-based changes.
Safety signals
Detect cell injury, tissue injury, and unexpected morphological changes early.
MoA confirmation
Connect target tissue response with immunostaining, molecular readouts, and pathway analysis.
Endpoint design
Narrow down endpoints and biomarker candidates before dog or cat studies.
Its value is in combining disease models, pathology, biomarkers, imaging, and gene expression to design what should be measured in dog or cat studies.
The questions to answer first differ by disease area
CKD and immuno-oncology are representative examples. KGAH-ONE is not limited to these areas. The appropriate nonclinical plan depends on the product, intended species, disease biology, expected mechanism, and the next planned study.
Look beyond renal function to what is happening in the kidney
In CKD development, teams may need to combine renal function markers such as BUN, creatinine, and GFR with tubular injury, interstitial fibrosis, inflammation, PAS staining, Sirius Red, gene expression, and inflammation/fibrosis markers to decide what should be measured in feline studies.
View Adenine-Induced CKD Model EvaluationBuild a map of immune response, not only tumor shrinkage
In immuno-oncology, tumor size alone may not explain response. T-cell infiltration, immune suppression, tumor microenvironment, checkpoint pathways, cytokines, and combination rationale may need to be read before dog or cat oncology studies.
Combine models and analyses according to the development question
Inflammation, fibrosis, dermatology, metabolic/liver disease, joint disease, oncology, and functional ingredients may each require different models, endpoints, pathology, and molecular analyses. The point is not the study menu; it is the information needed for the next development decision.
The real risk is not failure. It is failure without explanation.
If a dog or cat study does not produce the expected result and the nonclinical design was weak, the next development decision becomes difficult.
Common “uninterpretable failures”
Questions to resolve first in nonclinical studies
Note: This is a conceptual illustration of relative development burden. Actual costs vary depending on product type, species, sample size, region, endpoints, and study design.
KGAH-ONE’s role: designing the development decision, not just listing study menus
KGAH-ONE works with specialized partners such as SMC Laboratories to help Animal Health companies define the scientific questions that should be answered before dog or cat evaluation.
Development Question
What must be clarified before dog or cat studies?
KGAH-ONE
MoA, endpoint, biomarker, candidate selection, Go / No-Go, partner coordination
Specialized Partners
Nonclinical evaluation, disease models, pathology, biomarker and analytical capabilities
Define the question
Before asking “what study should we run,” define what must be learned before the next development step.
Connect mouse data to dog or cat study design
Mouse data should not replace later studies. It should help make them interpretable.
Coordinate the right execution path
KGAH-ONE coordinates specialized partners for model selection, pathology, endpoints, and analysis depending on the development question.
Public references used for context
These references are used to frame the broader problem: late-stage failure becomes more expensive when the scientific rationale and evaluation design remain unclear.
Before moving into dog or cat studies, clarify what the mouse study should tell you.
KGAH-ONE helps Animal Health companies organize development questions and coordinate specialized nonclinical evaluation through appropriate partners depending on the development question.